B cell-targeting strategies such as rituximab are widely used in B cell hematologic malignancies, rheumatologic and musculoskeletal diseases and a variety of autoimmune disorders. The purpose of this paper is to illustrate how exposure to anti-CD20 treatment profoundly affects B cell functions involved in anti-SARS-CoV-2 immunity and significantly impacts on the clinical and serological course of SARS-CoV-2 infection, long term immunity and vaccine responses. The data presented here suggest that the effects of B cell-depleting agents on adaptive immunity should be taken into account for the proper selection and interpretation of SARS-CoV-2 diagnostics and to guide appropriate therapeutic approaches and protective measures. Combination therapeutic strategies including immunotherapy in association with prolonged antiviral treatment may play a decisive role in the setting of B cell immune deficiencies.
【저자키워드】 COVID-19, SARS-CoV-2, rituximab, anti-CD20 therapy, B cell-depletion, B cell immunodeficiency, hyperimmune convalescent plasma, anti-SARS-CoV-2 monoclonal antibodies, 【초록키워드】 Adaptive immunity, adaptive, Immunity, Immunotherapy, SARS-COV-2 infection, Antiviral treatment, anti-SARS-CoV-2, diagnostics, immune, rituximab, B cell, Measures, Impact, Interpretation, serological, disease, therapeutic strategy, function, anti-CD20, Protective, association, Therapeutic approach, Autoimmune disorders, vaccine responses, long term, exposure to, Musculoskeletal, deficiencies, anti-CD20 treatment, malignancies, hematologic, Effect, Affect, Course, significantly, involved, variety, 【제목키워드】 challenge,